Daily non-political popular news in brief.

Group therapy fails to improve breast cancer survival

07-23-2007 · EurekAlert!

A follow up to a previous study on group therapy in breast cancer patients finds group therapy does not prolong the lives of women with metastatic breast cancer.

Keywords: group, therapy, fails, improve, breast, cancer, survival, fail

« Previous | Next »

Similar news on "Group therapy fails to improve breast cancer survival":

Bevacizumab found to improve survival for patients with advanced breast cancer
12-26-2007 · EurekAlert!
Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an antiangiogenic therapy. The study, published in the Dec. 27 issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.
Similar news · Read more »
New biomarker predicts effectiveness of breast cancer drugs
12-07-2006 · EurekAlert!
University of Cincinnati researchers have identified a new way to predict when anti-estrogen drug therapies are inappropriate for patients with hormone-dependent breast cancer.Scientists say these findings could help physicians more accurately predict which tumors will respond to anti-estrogen therapy and improve long-term survival for breast cancer patients.
Similar news · Read more »
Breast cancer survival rates improved by novel drug sequence, say researchers
02-12-2007 · EurekAlert!
Changing the way women are treated for breast cancer could improve their overall chance of survival, according to research published today in the Lancet. The new paper shows that switching to a drug called exemestane, two to three years after commencing standard therapy with the drug tamoxifen, can cut the risk of death for certain women by a further 17 percent compared with using tamoxifen alone.
Similar news · Read more »
Gene patenting -- steep cost for health care and patients
05-07-2007 · EurekAlert!
The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
Similar news · Read more »
Order of chemotherapy, radiation has no effect on breast cancer survival
10-30-2006 · EurekAlert!
For women who have had surgery for early breast cancer, it may not matter whether they receive follow-up chemotherapy before, after or during radiation therapy, according to a new review of studies.
Similar news · Read more »
Adding radiation therapy for treatment of advanced prostate cancer may offer benefit
11-14-2006 · EurekAlert!
Treating advanced prostate cancer with radiation therapy after removal of the prostate gland reduces the risk of disease recurrence, but does not appear to significantly improve the length of survival, according to a study in the Nov. 15 issue of JAMA, a theme issue on men's health.
Similar news · Read more »
Anthracyclines improve survival in HER2-positive breast cancer patients
12-25-2007 · EurekAlert!
Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online Dec. 25 in the Journal of the National Cancer Institute.
Similar news · Read more »
High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer
12-13-2007 · EurekAlert!
High-dose chemotherapy and autologous stem cell transplantation, the controversial, arduous, yet once-popular combination treatment that fell out of favor as a therapy for breast cancer, has proven not to be beneficial as an adjuvant therapy for women with node-positive disease, according to an expansive analysis conducted by researchers at the University of Texas M. D. Anderson Cancer Center.
Similar news · Read more »
Combining therapies can improve survival for early-stage breast cancer patients
04-03-2007 · EurekAlert!
Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression -- treatment to stop the ovaries from functioning -- did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.
Similar news · Read more »
Epigenetic drugs, promising for breast cancer treatment
12-20-2006 · EurekAlert!
Worldwide, cancer persists as one of the most important diseases that affect the human being. The knowledge on the molecular bases of cancer generated during the last decades has been successfully translated into small but significant gains in overall cancer survival rates due to better primary prevention measures, improved diagnostic methods and the development of more effective and specific therapies, collectively termed "molecular targeted therapies." In the context of these new forms of treatment, epigenetic or transcriptional cancer therapy is clearly promising.
Similar news · Read more »